BSD Medical Announces First Quarter Fiscal 2013 Financial Results

  BSD Medical Announces First Quarter Fiscal 2013 Financial Results

Business Wire

SALT LAKE CITY -- January 10, 2013

BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com),
a leading provider of medical systems that treat cancer and benign diseases
using heat therapy, today reported financial results for its first fiscal
quarter ended November 30, 2012, including:

  *Cash and cash equivalents of $9.1 million
  *No debt
  *Total stockholders’ equity of $12.6 million
  *MicroThermX^® revenues of $.5 million in Q1 2013 compared to $73,129 in Q1
    2012
  *Total revenues of $659,785
  *Current hyperthermia sales backlog of $935,000
  *Net loss of $2,218,664
  *Net cash used in operating activities of $1,955,831

“Total company revenues for the quarter ended November 30, 2012, were
essentially level when compared to revenues for the first quarter ended
November 30, 2011. This was due primarily to a decrease in sales associated
with our hyperthermia systems when comparing the two quarters. However, we
recently shipped a new BSD-500 Hyperthermia System and we currently have
additional sales backlog of four hyperthermia systems which we will deliver in
fiscal 2013,” said Harold Wolcott, President of the Company. “We are
encouraged by the progress we have made in our MicroThermX^® Microwave
Ablation System (“MicroThermX^®”) business. We experienced a 586% increase in
sales for the MicroThermX^® product line for the fiscal quarter ended November
30, 2012, as compared to the fiscal quarter ended November 30, 2011. We
continue to have good working capital, no long-term debt, and we will carry on
with investing in our sales and marketing and product development efforts.”

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy delivered using focused
radiofrequency (RF) and microwave energy. BSD’s product lines include both
hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the United
States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to ablate and destroy soft tissue. The Company has
developed extensive intellectual property, multiple products in the market,
and well established distribution in the United States, Europe and Asia.
Certain of the Company’s products have received regulatory approvals in the
United States, Europe and China. For further information visit BSD Medical's
website at www.BSDMedical.com.

Forward-Looking Statements

Statements contained in this press release that are not historical facts,
including statements relating to our MicroThermX^® line of products, are
forward-looking statements, as defined in the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are subject to risks and
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission, including the market demand for our MicroThermX^®
products and the regulatory requirements we face. These forward-looking
statements speak only as of the date on which such statements are made, and
the Company undertakes no obligation to update such statements to reflect
events or circumstances arising after such date, except as required by law.

Contact:

BSD Medical Corporation
Bill Barth, 801-972-5555
Facsimile: 801-972-5930
investor@bsdmc.com